Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa.

Cohen CR, Moscicki AB, Scott ME, Ma Y, Shiboski S, Bukusi E, Daud I, Rebbapragada A, Brown J, Kaul R.

AIDS. 2010 Aug 24;24(13):2069-74. doi: 10.1097/QAD.0b013e32833c323b.

2.

Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.

Sex Transm Dis. 2010 Feb;37(2):100-4. doi: 10.1097/OLQ.0b013e3181bc0aac.

PMID:
19823111
3.

Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.

van de Wijgert JH, Kilmarx PH, Jones HE, Karon JM, Chaikummao S.

Contraception. 2008 Feb;77(2):122-9. doi: 10.1016/j.contraception.2007.10.006. Epub 2007 Dec 27.

PMID:
18226677
4.

Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials.

Wallace AR, Teitelbaum A, Wan L, Mulima MG, Guichard L, Skoler S, Vilakazi H, Mapula FS, Rossier J, Govender SN, Lahteenmaki P, Maguire RA, Phillips DM.

Contraception. 2007 Jul;76(1):53-6. Epub 2007 May 11. Erratum in: Contraception. 2007 Oct;76(4):335. Skiler, Stephanie [corrected to Skoler, Stephanie].

PMID:
17586138
5.

Self-reported mechanical problems during condom use and semen exposure. Comparison of two randomized trials in the United States of America and Brazil.

Chen MP, Macaluso M, Blackwell R, Galvao L, Kulczycki A, Diaz J, Jamieson DJ, Duerr A.

Sex Transm Dis. 2007 Aug;34(8):557-62.

PMID:
17417133
6.

Detection and quantification of Y-chromosomal sequences by real-time PCR using the LightCycler system.

Melendez JH, Giles JA, Yuenger JD, Smith TD, Ghanem KG, Reich K, Zenilman JM.

Sex Transm Dis. 2007 Aug;34(8):617-9. No abstract available.

PMID:
17334265
7.

Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study.

Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M.

Contraception. 2006 Aug;74(2):133-40. Epub 2006 May 2.

8.

Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.

Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL.

Antimicrob Agents Chemother. 2006 May;50(5):1696-700.

9.

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L.

AIDS. 2005 Dec 2;19(18):2157-63.

PMID:
16284466
10.

Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.

Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S.

Antiviral Res. 2005 Dec;68(3):139-46. Epub 2005 Sep 27.

PMID:
16219368
11.

Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa.

Hoffman IF, Taha TE, Padian NS, Kelly CW, Welch JD, Martinson FE, Kumwenda NI, Rosenberg ZF, Chilongozi DA, Brown JM, Chirenje M, Richardson BA.

AIDS. 2004 Nov 5;18(16):2191-5.

PMID:
15577653
12.

In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE.

Antimicrob Agents Chemother. 2004 Oct;48(10):3834-44.

13.

A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.

Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R.

Contraception. 2004 Sep;70(3):233-40.

PMID:
15325893
14.
15.

Safety of single daily use for one week of C31G HEC gel in women.

Ballagh SA, Baker JM, Henry DM, Archer DF.

Contraception. 2002 Nov;66(5):369-75.

PMID:
12443969
16.

Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication.

Gong Y, Matthews B, Cheung D, Tam T, Gadawski I, Leung D, Holan G, Raff J, Sacks S.

Antiviral Res. 2002 Aug;55(2):319-29.

PMID:
12103432
17.

Recommendations for the clinical development of topical microbicides: an update.

Mauck C, Rosenberg Z, Van Damme L; International Working Group on Microbicides.

AIDS. 2001 May 4;15(7):857-68.

PMID:
11399958
18.

Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites.

van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):21-7.

PMID:
11176265
19.

Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.

Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z.

Clin Infect Dis. 2001 Feb 1;32(3):476-82. Epub 2001 Jan 26.

PMID:
11170957
20.

Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.

Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff J, Debyser Z, De Clercq E, Holan G, Pannecouque C.

Mol Pharmacol. 2000 Nov;58(5):1100-8.

Supplemental Content

Support Center